Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2, Open Label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Erlotinib With Or Without Pf 02341066 In Patients With Advanced Non Small Cell Adenocarcinoma Of The Lung.

NCT00965731 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00965731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00965731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2, Open Label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Erlotinib With Or Without Pf 02341066 In Patients With Advanced Non Small Cell Adenocarcinoma Of The Lung.
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2010
Completion date
January 31, 2014
Enrollment
27 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer